These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29318728)

  • 21. Long-term low-dose tolvaptan treatment in hospitalized male patients aged >90 years with hyponatremia: Report on safety and effectiveness.
    Liu YH; Han XB; Fei YH; Xu HT
    Medicine (Baltimore); 2017 Dec; 96(52):e9539. PubMed ID: 29384972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants.
    Marx-Berger D; Milford DV; Bandhakavi M; Van't Hoff W; Kleta R; Dattani M; Bockenhauer D
    Acta Paediatr; 2016 Jul; 105(7):e334-7. PubMed ID: 27028950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The treatment of hyponatraemia using vasopressin antagonists.
    Gross P; Palm C
    Exp Physiol; 2000 Mar; 85 Spec No():253S-257S. PubMed ID: 10795929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnosis and management of inpatient hyponatraemia and SIADH.
    Grant P; Ayuk J; Bouloux PM; Cohen M; Cranston I; Murray RD; Rees A; Thatcher N; Grossman A
    Eur J Clin Invest; 2015 Aug; 45(8):888-94. PubMed ID: 25995119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [From hyponatremia to tolvaptan].
    Cernaro V; Santoro D; Lacquaniti A; Montalto G; Buemi M
    G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans.
    Bhandari S; Peri A; Cranston I; McCool R; Shaw A; Glanville J; Petrakova L; O'Reilly K
    Clin Endocrinol (Oxf); 2017 Jun; 86(6):761-771. PubMed ID: 28214374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
    Li L; Bai H; Zhu WL;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):936-40. PubMed ID: 22321279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
    Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Where vaptans do and do not fit in the treatment of hyponatremia.
    Jovanovich AJ; Berl T
    Kidney Int; 2013 Apr; 83(4):563-7. PubMed ID: 23254896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Symptomatic therapy of SIADH in small cell lung cancer by tolvaptan].
    Schnaiter A; Hiddemann W
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2077-9. PubMed ID: 25268207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
    Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
    Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and treatment of hyponatraemia in neurosurgical patients.
    Cuesta M; Hannon MJ; Thompson CJ
    Endocrinol Nutr; 2016 May; 63(5):230-8. PubMed ID: 26965574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Etiology, diagnostics and therapy of hyponatremias].
    Laczi F
    Orv Hetil; 2008 Jul; 149(29):1347-54. PubMed ID: 18617466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
    Dahl E; Gluud LL; Kimer N; Krag A
    Aliment Pharmacol Ther; 2012 Oct; 36(7):619-26. PubMed ID: 22908905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia.
    Lee MY; Kang HJ; Park SY; Kim HL; Han E; Lee EK
    Clin Ther; 2014 Sep; 36(9):1183-94. PubMed ID: 25151571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S; Zhang X; Han T; Xie W; Li Y; Ma H; Liebe R; Weng H; Ding HG
    BMC Gastroenterol; 2018 Sep; 18(1):137. PubMed ID: 30180806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A case of venlafaxine-induced syndrome of inappropriate ADH secretion (SIADH) - treatment with tolvaptan].
    Meyer I; Frank D; Janssens U
    Dtsch Med Wochenschr; 2012 May; 137(21):1096-9. PubMed ID: 22588654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.